US 11,866,739 B2
Ligand binding molecules and uses thereof
Michael Gerometta, Robertson (AU); and Timothy Adams, Lower Plenty (AU)
Assigned to VEGENICS PTY LIMITED, South Yarra (AU)
Filed by VEGENICS PTY LIMITED, South Yarra (AU)
Filed on Oct. 4, 2019, as Appl. No. 16/593,750.
Application 15/639,573 is a division of application No. 14/768,701, granted, now 9,745,558, previously published as PCT/AU2014/000114, filed on Feb. 13, 2014.
Application 16/593,750 is a continuation of application No. 15/639,573, filed on Jun. 30, 2017, granted, now 10,494,617.
Claims priority of provisional application 61/782,376, filed on Mar. 14, 2013.
Claims priority of provisional application 61/765,841, filed on Feb. 18, 2013.
Prior Publication US 2020/0165584 A1, May 28, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/12 (2006.01); C07K 14/71 (2006.01); A61K 47/64 (2017.01); A61K 45/06 (2006.01); A61K 38/45 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/12 (2013.01) [A61K 38/45 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61K 47/64 (2017.08); C07K 14/71 (2013.01); C07K 16/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/70 (2013.01); C12N 2710/10043 (2013.01); C12Y 207/10001 (2013.01)] 19 Claims
 
1. A method of treating a subject having an ocular disorder associated with neovascularization, vascular endothelial cell proliferation, vascular permeability, edema or inflammation, the method comprising
administering to the subject a composition comprising:
(i) a soluble, ligand binding molecule comprising a ligand binding polypeptide, wherein the ligand binding polypeptide comprises an amino acid sequence having at least 95% identity to the sequence of amino acids defined by positions 47-115 of SEQ ID NO: 2, with the proviso that positions of the polypeptide corresponding to positions 104-106 of SEQ ID NO: 2 are not identical to N-X-S or N-X-T, and wherein the ligand binding polypeptide and the ligand binding molecule bind to at least one ligand polypeptide selected from human VEGF-C, VEGF-D, and PIGF; and
(ii) a pharmaceutically acceptable diluent, adjuvant, excipient, or carrier;
the method comprising administering to the subject the composition in an amount effective to inhibit neovascularization, vascular endothelial cell proliferation, vascular permeability, edema, or inflammation in the subject.